TLDR
- BIIB hit a 52-week high of $225.88, up 61.6% over the past year
- Nykredit A/S made a new $8.02 million investment in Biogen in Q2
- Q2 EPS of $3.60 beat estimates of $2.94; revenue of $2.74B topped forecasts
- Analysts hold a “Moderate Buy” consensus with an average price target of $230.14
- Wolfe Research upgraded BIIB to “Outperform” with a $300 price target in August
Biogen stock reached a 52-week high of $225.88 on Monday, continuing a strong run that has seen the stock climb 61.6% over the past year.
The stock opened at $219.07 on Tuesday, trading up around 1.7% on the day. Its 50-day moving average sits at $211.20, and its 200-day moving average is $198.54.
The 1-year low was $135.39, making the current level a sharp recovery from where the stock sat just 12 months ago.
Biogen’s market cap stands at roughly $32.37 to $33.26 billion, depending on the trading session, with a P/E ratio in the range of 38.77 to 39.41.
Strong Earnings Fuel Momentum
The stock’s climb has been backed by solid fundamentals. In its most recent quarterly earnings, Biogen posted EPS of $3.60, beating the consensus estimate of $2.94 by $0.66.
Revenue came in at $2.74 billion, topping the $2.46 billion estimate and growing 3.4% year over year.
For full-year 2026, Biogen has guided for EPS of $12.00 to $13.00. Analysts currently expect $12.41 EPS for the fiscal year.
Institutional investors are clearly paying attention. Nykredit A/S picked up 37,134 BIIB shares in Q2, valued at around $8.02 million.
Other firms added to existing positions. Wedbush Securities raised its stake by 5.1% in Q2. Rothschild Investment, Meeder Advisory, Kera Capital, and Parallel Advisors all added to their holdings earlier in the year.
Institutions collectively own 87.93% of Biogen’s outstanding stock.
Analyst Targets and Upgrades
The analyst community has been warming up to the name. Wolfe Research upgraded BIIB from “Peer Perform” to “Outperform” in August, setting a $300 price target.
Oppenheimer reaffirmed its “Outperform” rating with a $300 target. Canaccord Genuity raised its target from $245 to $248, maintaining a Buy.
RBC Capital lifted its target to $260 from $240, pointing to the lupus drug litifilimab as a key upcoming catalyst. H.C. Wainwright moved its target to $251 from $237 for the same reason.
Piper Sandler raised its target to $245 from $225, citing stronger model estimates for drugs including Vumerity and Syfovre. Stifel holds a Buy with a $242 target.
The current consensus across 33 analysts is “Moderate Buy,” with an average price target of $230.14.
InvestingPro’s Fair Value model suggests the stock may still be undervalued at current levels.
Biogen also recently committed to deploying Veeva Systems’ Vault CRM globally, a move noted by Raymond James analysts as part of a broader pharma industry trend.
Results from litifilimab’s phase 3 lupus trials are expected later this year, with Stifel among those expressing confidence in the outcome.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
